Richard Wood Storrs



Hanuman Medical
PlasmaSeal L.L.C.
Cerco Medical, L.L.C.
2180 Palou Ave.
San Francisco, CA 94124
(415) 643-2763




SKILLS SUMMARY

  •  Drug development from molecular modeling to pre-clinical
  •  Bio-chemicalStructure / Function relationships
  •  Productive, pick up and deliver on new projects
  •  Creative problem solver, excellent communication skills

EMPLOYMENT

Vice President (March 2002-present), Scientist and Chief Actuator (March 1998-March 2002),Research and Development, Hanuman Medical LLC. 2180 Palou Ave. San Francisco, CA  94124 Hanuman comprises PlasmaSeal L.L.C. and Islet Sheet Medical L.L.C.

PlasmaSeal makes a device for intra-operative production of autologous plasma concentrate for hemostasis.  I am responsible for prototype device design, fabrication and optimization, testing of plasma concentrates for strength, stability, plasma component concentration and integrity, as well as pre-clinical testing of hemostatic and wound healing properties in rodents and large animals.  Where these studies were performed with third parties I am responsible for establishing contacts, study design, approval and implementation.  I am also responsible for related products designed for stat production of platelet concentrate for orthopedic and soft tissue wound healing.

The Islet Sheet is a hydrogel device for immuno-isolation of cellular implants, e.g. Islets of Langerhans for reversal of Type-1 diabetes.  My responsibilities include process development, device manufacture, biophysical assessment of product dimensions and permselectivity, and oversight of pre-clinical studies of toxicity, stability and efficacy in rodent and large animal models.  Preclinical parameters include histological assessment of host response to implant material and disposition of implanted cells, as well as metabolic assessment of encapsulated cell function.  Participated in primary islet isolation, purification, culture and functional status.  Responsible for hydrogel purification and characterization.    One patent issued, two peer-reviewed publications.

Scientist and Project Leader, DepoTech Advanced Technologies [now SkyePharma](Jan. 1996-Feb. 1998).  10450 Science Center Dr.  San Diego, CA  92121.  DepoTech is developing a lipid-based sustained-release formulation of several pharmaceutics, one of which (DepoCyt) is FDA approved.   I was responsible for development of new applications and feasibility testing of new products for anti-inflammatory and anti-thrombotic indications. Formulation of proprietary and generic drugs, in vitro stability and in vivo pharmacokinetic/pharmacodynamic testing were core responsibilities. Developed formulation with highest historical mass-loading of active drug (a heparinoid) and unprecedented formulation with lipophilic active agents (corticosteroids).  Established preclinical models of inflammation in rodents and rabbits.  Assisted in PK/PD assessment of anti-CMV agents administered intraocularly.  Also contributed to the basic biophysical characterization of formulated lipid aggregates, particularly the interaction of active encapsulant with the lipid structure.

EDUCATION

Stanford University

Postdoctoral Research Fellow

(Radiology)

Jan. ‘93- Dec. ‘95

Development of Targeted Intravascular Contrast Reagents

(w/ King Li, M.D.)

1 patent,

2 publications; Targesome, Inc

Detection of Apoptosis In Vivo

(w/Francis Blankenberg, M.D.)

NIH Fellowship

2 publications;

Theseus Imaging Corp.

U. Calif. Berkeley

Ph.D.

(Chemistry, w/

DE Wemmer)

Aug. ‘84-Dec. ‘92

Spectroscopic and Functional Studies of Catalytic Antibodies and Small Highly Structured Peptides

1 book chapter

2 publications

Amherst College

B.A.

(Chemistry)

Aug. ‘80-May ‘84

An NMR Approach to the Study of Model Bile Mixtures

Magna cum laude

2 publications

 

Experience

Dr. Storrs has demonstrated abilities as a Project Manager in biotechnology.  He is the co-inventor of numerous drug delivery systems, has experience with both new and established preclinical models of disease and is proficient in histological assessment of host response to implant material and disposition of implanted cells. At Cerco Medical LLC he developed experitise in primary islet isolation, purification, culture and functional status; metabolic assessment of encapsulated cell function; biophysical assessment of product dimensions and permselectivity; hydrogel purification and characterization.  At Hanuman Medical LLC he was responsible for testing of plasma concentrates for strength, stability, plasma component concentration and integrity; and pre-clinical testing of hemostatic and wound healing properties in rodents and large animals.  At DepoTech Corp. his responsibilities included basic biophysical characterization of formulated lipid aggregates (particularly the interaction of active encapsulant with the lipid structure), formulation of proprietary and generic drugs, in vitro stability and in vivo pharmacokinetic/pharmacodynamic testing in models of CMV retinitis, deep-vein thrombosis and chronic inflammation.

Accomplishments

Dr. Storrs has demonstrated ability to transform concepts from an idea to a proven prototype.  For PlasmaSeal LLC, he has developed a prototype device design, fabrication and an optimization of devices for intra-operative production of autologous plasma concentrate for hemostasis and created and implemented various study designs for this device as well as related products designed for stat production of platelet concentrate for orthopedic and soft tissue wound healing. For Cerco Medical LLC he has been responsible for process development, device manufacture, and pre-clinical studies of toxicity, stability and efficacy in rodent and large animal models in developing the Islet Sheet.  At DepoTech he developed the formulation with highest historical mass-loading of active drug (a heparinoid) and an unprecedented formulation with lipophilic active agents (corticosteroids); established preclinical models of inflammation in rodents and rabbits; developed new applications and feasibility testing of new products for anti-inflammatory and anti-thrombotic indications for lipid-based sustained-release formulation of several pharmaceutics,  including FDA approved DepoCyt.

 

TECHNICAL SKILLS

Preclinical Assessment          ·                            host response to implant materials

                                          ·    animal models of disease (diabetes, tumor xenografts, ischemia)

  • biodistribution, pharmacokinetics / pharmacodynamics

Cellular Biology             ·     primary islet isolation

                                          ·     mammalian cell culture, cloning

                                          ·     mg-scale protein expression

                                          ·     cellular encapsulation

Protein chemistry           ·     peptide synthesis and purification

  • monoclonal antibody technology
  • carrier coupling reactions, affinity purification
  • structure analysis, structure/function relationships
  • computation and molecular modeling

Biomolecular characterization

  • structure and dynamics by optical and magnetic resonance spectroscopies
  • chromatographic separations including HPLC and affinity
  • binding assays for carbohydrates, peptides, nucleic acids
  • transmission electron microscopy
  • particle size analysis by light scattering

Liposome technology           ·                            developed sustained release formulations

  • synthesized new polymerizable lipids and complexes
  • constructed and characterized intravascular recirculating formulations
  • derivatized liposome surfaces for molecular targeting

 

AWARDS                     ·                                NIH National Research Service Award

  •  Dean’s Postdoctoral Fellowship, Stanford School of Medicine
  •  Henry Waters Doughty Prize for best thesis
  •  Magna cum laude, Amherst College

Selected peer-reviewed publications

  1. Storrs,Richard W., Dorian, R. King, S.R., Lakey, J. and Rilo, H. (2001)  Preclinical Development of the Islet Sheet.  Annals of the New York Academy of Sciences Vol. 944.
  2. King, S.R., Dorian, R. Storrs, Richard W., Lakey J., (2001)  Requirements for Encapsulation Technology and the Challenges for Transplantation of Islets of Langerhans.  Graft Vol. 4(7), pp. 491-9
  3. Blankenberg, F. Katsikis, P., Storrs, Richard W., Beaulieu, C. Spielman, D., Chen, J., Naumovski, L., and Tait, J. (1997) Quantitative Analysis of Apoptotic Cell Death Using Proton Nuclear Magnetic Resonance Spectroscopy  Blood Vol. 89(10), pp. 3778-3786
  4. Blankenberg, F., Storrs, Richard W., Naumovski, L., Goralski, T., and Spielman, D. (1996)  Detection of Apoptotic Cell Death by Proton Nuclear Magnetic Resonance Spectroscopy,.  Blood Vol. 87(5), pp. 1951-1956,
  5. Storrs, Richard W., Tropper, F., Li, H., Song, C., Sipkins,  D., Kuniyoshi, J.,  Bednarski, M., and Li, K.. (1995)  Paramagnetic Polymerized Liposomes as New Recirculating MR Contrast Agents,  J. Magn. Res. Imaging Vol. 5(6) pp. 719-724
  6. Storrs, Richard W.,  Tropper, F., Li, H., Song, C., Sipkins,  D., Kuniyoshi, J.,  Dorothy A.,  Li, K..,  and Bednarski, M. (1995)  Paramagnetic Polymerized Liposomes for Magnetic Resonance Imaging:  Synthesis and Characterization,.  J. Am. Chem. Soc. Vol. 117(28), pp. 7301-7306.
  7. Storrs, Richard W., Truckses, D., and Wemmer, D.  (1992) Helix Propagation in Trifluoroethanol Solutions, Biopolymers Vol. 32(12), pp. 1695-1702.
  8. Pease, J., Storrs, Richard W., and Wemmer, D. (1990)  Folding and Activity of Hybrid Sequence, Disulfide-Stabilized Peptides,.  Proc. Natl. Acad. Sci., USA  Vol. 87, pp. 5643-7, August.
  9. Nall, D. and Dill, K., eds (1991) Chapter 6 of Conformations and Forces in Protein Folding, (pp.77-85. AAAS, Washington D.C.
  10. Stark, R., Storrs, Richard W.,  Levine, S., Yee, S, and Broido, M.  (1986)  One- and Two- Dimensional NMR Relaxation Studies of Dynamics and Structure in Bile Salt-Phosphatidylcholine Mixed Micelles. Biochemica et Biophysica Acta Vol. 860 pp. 399-410,
  11. Stark, R., Storrs, Richard W., and Kasakevich, M. (1985)  Nuclear Magnetic Resonance Studies of Solubilization in w-Phenylalkanoate-SDS Mixtures.  The Journal of Physical Chemistry Vol. 89, pp. 272-7.

 

Patents and patent applications

  1. U.S. Patent application No. 20030205538 (2003).  Dorian, Randel E.; King, Scott R.; Storrs, Richard W. Methods and apparatus for isolating platelets from blood.
  2. U.S. Patent No. 6,569,451 (2003); Li, King C.; Bednarski, Mark D.; Storrs, Richard W. ; Li, Henry Y.; Trooper, Francois D.; Song, Curtis K. H.; Sipkins, Dorothy A.; Kuniyoshi, Jeremy K. Targeted polymerized liposome diagnostic and treatment agents.
  3. U.S. Patent No. 6,350,466 (2002); Li, King C.; Bednarski, Mark D.; Storrs, Richard W.; Li, Henry Y.; Trooper, Francois D.; Song, Curtis K. H.; Sipkins, Dorothy A.; Kuniyoshi, Jeremy K. Targeted polymerized liposome diagnostic and treatment agents.
  4. U.S. Patent No. 6,132,764 (2000); Li, King C.; Bednarski, Mark D.; Storrs, Richard W.; Li, Henry Y.; Trooper, Francois D.; Song, Curtis K. H.; Sipkins, Dorothy A.; Kuniyoshi, Jeremy K. Targeted polymerized liposome diagnostic and treatment agents.
  5. U.S. Patent No. 6,090,408 (2000); Li, King C.; Bednarski, Mark D.; Storrs, Richard W.; Li, Henry Y.; Trooper, Francois D.; Song, Curtis K. H.; Sipkins, Dorothy A.; Kuniyoshi, Jeremy K. Use of polymerized lipid diagnostic agents.
  • U.S. Patent No. 5,512,294 (1996); Li, King C.; Bednarski, Mark D.; Storrs, Richard W.; Li, Henry Y.; Trooper, Francois D.; Song, Curtis K. H.; Sipkins, Dorothy A.; Kuniyoshi, Jeremy K. Targeted Polymerized Liposome Contrast Agents.